These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 19788245)
1. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. Lamoral-Theys D; Andolfi A; Van Goietsenoven G; Cimmino A; Le Calvé B; Wauthoz N; Mégalizzi V; Gras T; Bruyère C; Dubois J; Mathieu V; Kornienko A; Kiss R; Evidente A J Med Chem; 2009 Oct; 52(20):6244-56. PubMed ID: 19788245 [TBL] [Abstract][Full Text] [Related]
2. Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. Van Goietsenoven G; Andolfi A; Lallemand B; Cimmino A; Lamoral-Theys D; Gras T; Abou-Donia A; Dubois J; Lefranc F; Mathieu V; Kornienko A; Kiss R; Evidente A J Nat Prod; 2010 Jul; 73(7):1223-7. PubMed ID: 20550100 [TBL] [Abstract][Full Text] [Related]
3. In search of a cytostatic agent derived from the alkaloid lycorine: synthesis and growth inhibitory properties of lycorine derivatives. Evdokimov NM; Lamoral-Theys D; Mathieu V; Andolfi A; Frolova LV; Pelly SC; van Otterlo WA; Magedov IV; Kiss R; Evidente A; Kornienko A Bioorg Med Chem; 2011 Dec; 19(23):7252-61. PubMed ID: 22019045 [TBL] [Abstract][Full Text] [Related]
4. Lycorine: A prospective natural lead for anticancer drug discovery. Roy M; Liang L; Xiao X; Feng P; Ye M; Liu J Biomed Pharmacother; 2018 Nov; 107():615-624. PubMed ID: 30114645 [TBL] [Abstract][Full Text] [Related]
5. C1,C2-ether derivatives of the Amaryllidaceae alkaloid lycorine: retention of activity of highly lipophilic analogues against cancer cells. Dasari R; Banuls LM; Masi M; Pelly SC; Mathieu V; Green IR; van Otterlo WA; Evidente A; Kiss R; Kornienko A Bioorg Med Chem Lett; 2014 Feb; 24(3):923-7. PubMed ID: 24393582 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. Ingrassia L; Lefranc F; Dewelle J; Pottier L; Mathieu V; Spiegl-Kreinecker S; Sauvage S; El Yazidi M; Dehoux M; Berger W; Van Quaquebeke E; Kiss R J Med Chem; 2009 Feb; 52(4):1100-14. PubMed ID: 19199649 [TBL] [Abstract][Full Text] [Related]
7. Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of β-catenin and matrix metallopeptidase 9. Zhang P; Zhang M; Yu D; Liu W; Hu L; Zhang B; Zhou Q; Cao Z J Cell Physiol; 2019 Jul; 234(7):10566-10575. PubMed ID: 30565685 [TBL] [Abstract][Full Text] [Related]
8. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. Hu M; Peng S; He Y; Qin M; Cong X; Xing Y; Liu M; Yi Z Oncotarget; 2015 Jun; 6(17):15348-61. PubMed ID: 25915156 [TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 1 as a potential target for lycorine against hepatocellular carcinoma. Yin S; Yang S; Luo Y; Lu J; Hu G; Wang K; Shao Y; Zhou S; Koo S; Qiu Y; Wang T; Yu H Biochem Pharmacol; 2021 Nov; 193():114806. PubMed ID: 34673013 [TBL] [Abstract][Full Text] [Related]
10. Lycorine inhibits cell proliferation, migration and invasion, and primarily exerts Zhang P; Yuan X; Yu T; Huang H; Yang C; Zhang L; Yang S; Luo X; Luo J Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649853 [TBL] [Abstract][Full Text] [Related]
11. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression. Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. Nair JJ; van Staden J Nat Prod Commun; 2014 Aug; 9(8):1193-210. PubMed ID: 25233606 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies on the lycorine pharmacophore: A potent inducer of apoptosis in human leukemia cells. McNulty J; Nair JJ; Bastida J; Pandey S; Griffin C Phytochemistry; 2009 May; 70(7):913-9. PubMed ID: 19464034 [TBL] [Abstract][Full Text] [Related]
14. Lycorine inhibits melanoma A375 cell growth and metastasis through the inactivation of the PI3K/AKT signaling pathway. Jiang QQ; Liu WB Med Sci (Paris); 2018 Oct; 34 Focus issue F1():33-38. PubMed ID: 30403172 [TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753 [TBL] [Abstract][Full Text] [Related]
16. Lycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathway. Wang J; Xu J; Xing G Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):771-779. PubMed ID: 28910973 [TBL] [Abstract][Full Text] [Related]
17. Lycorine inhibits cell proliferation and migration by inhibiting ROCK1/cofilin‑induced actin dynamics in HepG2 hepatoblastoma cells. Liu W; Zhang Q; Tang Q; Hu C; Huang J; Liu Y; Lu Y; Wang Q; Li G; Zhang R Oncol Rep; 2018 Oct; 40(4):2298-2306. PubMed ID: 30066939 [TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity and virtual screening by molecular docking of lycorine from Pancratium foetidum Pom (Moroccan endemic Amaryllidaceae). Bendaif H; Melhaoui A; Ramdani M; Elmsellem H; Douez C; El Ouadi Y Microb Pathog; 2018 Feb; 115():138-145. PubMed ID: 29253598 [TBL] [Abstract][Full Text] [Related]
19. Lycorine derivatives against Trichomonas vaginalis. Giordani RB; Junior CO; de Andrade JP; Bastida J; Zuanazzi JA; Tasca T; de Almeida MV Chem Biol Drug Des; 2012 Jul; 80(1):129-33. PubMed ID: 22260620 [TBL] [Abstract][Full Text] [Related]
20. 5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells. Henry S; Kidner R; Reisenauer MR; Magedov IV; Kiss R; Mathieu V; Lefranc F; Dasari R; Evidente A; Yu X; Ma X; Pertsemlidis A; Cencic R; Pelletier J; Cavazos DA; Brenner AJ; Aksenov AV; Rogelj S; Kornienko A; Frolova LV Eur J Med Chem; 2016 Sep; 120():313-28. PubMed ID: 27218860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]